Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,443 across all filing types
Latest filing 2017-11-22 Capital/Financing Update
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
IMUGENE RAISES $8.7 MILLION 5 pages 72.8KB
Capital/Financing Update Classification · 100% confidence The document is an ASX release dated 23 November 2017 from Imugene Limited announcing a capital raising of $8.7 million through a placement and a fully underwritten entitlement offer. It details the structure of the equity raising, pricing, use of proceeds, key dates, and other relevant information about the offering. There are no financial statements or detailed financial performance data included, nor is this a transcript, management report, or regulatory filing of another type. The document is clearly an update on the company's fundraising activities and capital structure changes. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is over 14,000 characters, indicating it is a full announcement rather than a brief notice or report publication announcement.
2017-11-22 English
Prospectus 45 pages 969.3KB
Capital/Financing Update Classification · 100% confidence The document is titled 'PROSPECTUS' and relates to a fully underwritten non-renounceable pro rata entitlement offer of new shares and options by Imugene Limited. It includes detailed information about the offer price, number of shares and options to be issued, use of proceeds, important dates, and shareholding structure. The content is focused on a capital raising event, specifically an equity raising through a share issue. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is not an annual or interim report, audit report, or earnings release, nor is it a regulatory filing or announcement of a report. It is a detailed prospectus for a share issue, which fits squarely into the Capital/Financing Update category.
2017-11-22 English
CAPITAL RAISING PRESENTATION 32 pages 13.4MB
Capital/Financing Update Classification · 95% confidence The document is titled 'CAPITAL RAISING PRESENTATION' and includes detailed information about a capital raising event, including the amount raised, offer price, structure of the raising (placement and entitlement offer), use of funds, timeline, and company overview. It is clearly a presentation aimed at investors to inform them about the capital raising initiative. There are no financial statements or detailed financial results presented, nor is this a regulatory announcement or a report publication notice. The content is consistent with an investor presentation focused on financing activities and company strategy related to capital raising.
2017-11-22 English
Appendix 3B 15 pages 222.6KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the number and class of shares and options issued, issue price, purpose of the issue, security holder approvals, underwriting details, and quotation application to the ASX. It references specific ASX rules and compliance requirements related to new share issues. The content is focused on announcing and detailing a new share issue and application for quotation of additional securities, which aligns with announcements regarding share issues or capital changes. There is no indication that this is a full financial report, audit, earnings release, or management discussion. The document is not a report publication announcement but the actual announcement of a capital raising event. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and detail support a high confidence in this classification.
2017-11-22 English
Imugene Entitlement Offer notice to eligible shareholders 3 pages 56.3KB
Capital/Financing Update Classification · 95% confidence The document is a detailed notice to shareholders about an entitlement offer and placement to raise equity capital. It includes information about the offer terms, eligibility, timetable, and regulatory compliance references such as the Corporations Act and ASIC prospectus lodgement. The content focuses on fundraising activities and capital structure changes, specifically an equity raising through share placement and entitlement offer. There are no financial statements, audit opinions, or management discussions of financial results. The document is not a report but an announcement and detailed notice regarding capital raising. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2017-11-22 English
Imugene Entitlement Offer notice to ineligible shareholders 2 pages 48.1KB
Capital/Financing Update Classification · 95% confidence The document is a notice to ineligible shareholders regarding an entitlement offer and institutional placement by Imugene Limited. It details the terms of the equity raising, eligibility criteria for shareholders, and the underwriting arrangement. The content focuses on informing shareholders about the equity raising and their ineligibility to participate, rather than presenting financial results or detailed financial statements. It is an announcement related to capital raising activities, specifically an entitlement offer and placement. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive information about the financing event, not just a brief announcement or a report publication notice.
2017-11-22 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.